Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: Implications for therapy

J. Fueyo, C. Gomez-Manzano, V. K. Puduvalli, P. Martin-Duque, Roman Perez-Soler, V. A. Levin, W. K A Yung, A. P. Kyritsis

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Malignant gliomas are highly resistant to chemotherapy, in part because of the blood-brain barrier, which restricts the delivery of chemotherapy to certain areas of tumor and their cellular heterogeneity, which leads to the selection and propagation of resistant clones. However, the molecular basis of the drug resistance is poorly understood. In this study, we examined the effect of the cell cycle-inhibitory protein p16 on the chemosensitivity of human glioma cells. Treatment of the pl6-null glioma cells, U-251 MG and D-54 MG, with paclitaxel and topotecan, resulted in cell death within 4 days. However, overexpression of exogenous wild-type p16 protein using an adenovirus vector resulted in G1, arrest of glioma cells and resistance to the anticancer effect of paclitaxel or topotecan. Specifically, the pl6-expressing cells showed a 30-fold increase in the ID50 of topotecan and a more than 40-fold increase in the ID50 of paclitaxel. These observations indicate that overexpression of molecules that control cell-cycle progression may be partially responsible for causing the resistance of glioma cells to cytocidal drugs.

Original languageEnglish (US)
Pages (from-to)665-669
Number of pages5
JournalInternational Journal of Oncology
Volume12
Issue number3
StatePublished - Mar 1998
Externally publishedYes

Fingerprint

Topotecan
Paclitaxel
Adenoviridae
Glioma
Therapeutics
Drug Therapy
Null Lymphocytes
Cell Cycle Proteins
Cell Cycle Checkpoints
Blood-Brain Barrier
Drug Resistance
Cell Death
Clone Cells
Pharmaceutical Preparations
Neoplasms
Proteins

Keywords

  • Glioma
  • p16
  • Paclitaxel
  • Topotecan
  • Tumor suppressor genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fueyo, J., Gomez-Manzano, C., Puduvalli, V. K., Martin-Duque, P., Perez-Soler, R., Levin, V. A., ... Kyritsis, A. P. (1998). Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: Implications for therapy. International Journal of Oncology, 12(3), 665-669.

Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan : Implications for therapy. / Fueyo, J.; Gomez-Manzano, C.; Puduvalli, V. K.; Martin-Duque, P.; Perez-Soler, Roman; Levin, V. A.; Yung, W. K A; Kyritsis, A. P.

In: International Journal of Oncology, Vol. 12, No. 3, 03.1998, p. 665-669.

Research output: Contribution to journalArticle

Fueyo, J, Gomez-Manzano, C, Puduvalli, VK, Martin-Duque, P, Perez-Soler, R, Levin, VA, Yung, WKA & Kyritsis, AP 1998, 'Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: Implications for therapy', International Journal of Oncology, vol. 12, no. 3, pp. 665-669.
Fueyo, J. ; Gomez-Manzano, C. ; Puduvalli, V. K. ; Martin-Duque, P. ; Perez-Soler, Roman ; Levin, V. A. ; Yung, W. K A ; Kyritsis, A. P. / Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan : Implications for therapy. In: International Journal of Oncology. 1998 ; Vol. 12, No. 3. pp. 665-669.
@article{4df78be4006041bcb6325e887ceabb93,
title = "Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: Implications for therapy",
abstract = "Malignant gliomas are highly resistant to chemotherapy, in part because of the blood-brain barrier, which restricts the delivery of chemotherapy to certain areas of tumor and their cellular heterogeneity, which leads to the selection and propagation of resistant clones. However, the molecular basis of the drug resistance is poorly understood. In this study, we examined the effect of the cell cycle-inhibitory protein p16 on the chemosensitivity of human glioma cells. Treatment of the pl6-null glioma cells, U-251 MG and D-54 MG, with paclitaxel and topotecan, resulted in cell death within 4 days. However, overexpression of exogenous wild-type p16 protein using an adenovirus vector resulted in G1, arrest of glioma cells and resistance to the anticancer effect of paclitaxel or topotecan. Specifically, the pl6-expressing cells showed a 30-fold increase in the ID50 of topotecan and a more than 40-fold increase in the ID50 of paclitaxel. These observations indicate that overexpression of molecules that control cell-cycle progression may be partially responsible for causing the resistance of glioma cells to cytocidal drugs.",
keywords = "Glioma, p16, Paclitaxel, Topotecan, Tumor suppressor genes",
author = "J. Fueyo and C. Gomez-Manzano and Puduvalli, {V. K.} and P. Martin-Duque and Roman Perez-Soler and Levin, {V. A.} and Yung, {W. K A} and Kyritsis, {A. P.}",
year = "1998",
month = "3",
language = "English (US)",
volume = "12",
pages = "665--669",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan

T2 - Implications for therapy

AU - Fueyo, J.

AU - Gomez-Manzano, C.

AU - Puduvalli, V. K.

AU - Martin-Duque, P.

AU - Perez-Soler, Roman

AU - Levin, V. A.

AU - Yung, W. K A

AU - Kyritsis, A. P.

PY - 1998/3

Y1 - 1998/3

N2 - Malignant gliomas are highly resistant to chemotherapy, in part because of the blood-brain barrier, which restricts the delivery of chemotherapy to certain areas of tumor and their cellular heterogeneity, which leads to the selection and propagation of resistant clones. However, the molecular basis of the drug resistance is poorly understood. In this study, we examined the effect of the cell cycle-inhibitory protein p16 on the chemosensitivity of human glioma cells. Treatment of the pl6-null glioma cells, U-251 MG and D-54 MG, with paclitaxel and topotecan, resulted in cell death within 4 days. However, overexpression of exogenous wild-type p16 protein using an adenovirus vector resulted in G1, arrest of glioma cells and resistance to the anticancer effect of paclitaxel or topotecan. Specifically, the pl6-expressing cells showed a 30-fold increase in the ID50 of topotecan and a more than 40-fold increase in the ID50 of paclitaxel. These observations indicate that overexpression of molecules that control cell-cycle progression may be partially responsible for causing the resistance of glioma cells to cytocidal drugs.

AB - Malignant gliomas are highly resistant to chemotherapy, in part because of the blood-brain barrier, which restricts the delivery of chemotherapy to certain areas of tumor and their cellular heterogeneity, which leads to the selection and propagation of resistant clones. However, the molecular basis of the drug resistance is poorly understood. In this study, we examined the effect of the cell cycle-inhibitory protein p16 on the chemosensitivity of human glioma cells. Treatment of the pl6-null glioma cells, U-251 MG and D-54 MG, with paclitaxel and topotecan, resulted in cell death within 4 days. However, overexpression of exogenous wild-type p16 protein using an adenovirus vector resulted in G1, arrest of glioma cells and resistance to the anticancer effect of paclitaxel or topotecan. Specifically, the pl6-expressing cells showed a 30-fold increase in the ID50 of topotecan and a more than 40-fold increase in the ID50 of paclitaxel. These observations indicate that overexpression of molecules that control cell-cycle progression may be partially responsible for causing the resistance of glioma cells to cytocidal drugs.

KW - Glioma

KW - p16

KW - Paclitaxel

KW - Topotecan

KW - Tumor suppressor genes

UR - http://www.scopus.com/inward/record.url?scp=0031883487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031883487&partnerID=8YFLogxK

M3 - Article

C2 - 9472109

AN - SCOPUS:0031883487

VL - 12

SP - 665

EP - 669

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -